Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence ...

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...